Semaglutide vs Dulaglutide — Efficacy
Semaglutide and dulaglutide are both once-weekly GLP-1 receptor agonists with established efficacy in type 2 diabetes. However, they differ in receptor binding kinetics, clinical trial evidence, and magnitude of metabolic effects. Understanding their distinct efficacy profiles informs rational GLP-1 RA selection.
Molecular Comparison
Section titled “Molecular Comparison”Dulaglutide
Section titled “Dulaglutide”Dulaglutide (Trulicity) is a GLP-1 analogue fused to an IgG4 Fc domain:
- GLP-1 component: [Gly⁸, Arg³⁴] GLP-1 (7-37)
- Fc fusion: Human IgG4 Fc domain → FcRn-mediated recycling
- Molecular weight: ~64 kDa (large molecule)
- Half-life: ~5 days (once-weekly dosing)
- Receptor: GLP-1R (EC₅₀ ~0.5 nM)
The Fc fusion strategy extends half-life through neonatal Fc receptor (FcRn)-mediated recycling — the GLP-1-Fc conjugate binds FcRn in endosomes and is recycled to the cell surface rather than degraded in lysosomes.
Semaglutide
Section titled “Semaglutide”Semaglutide (Ozempic/Wegovy) uses albumin binding for half-life extension:
- Sequence: Human GLP-1 with Aib⁸ and Arg³⁴ substitution
- Acylation: C-18 fatty diacid via linker at Lys²⁶ → albumin binding
- Molecular weight: ~4.1 kDa (small molecule)
- Half-life: ~7 days (once-weekly dosing)
- Receptor: GLP-1R (EC₅₀ ~0.2 nM)
Semaglutide’s stronger albumin binding and higher GLP-1R affinity (2.5× greater than dulaglutide) may underlie its greater metabolic effects.
Clinical Trial Evidence
Section titled “Clinical Trial Evidence”AWARD Program (Dulaglutide)
Section titled “AWARD Program (Dulaglutide)”The AWARD program established dulaglutide’s efficacy across multiple populations:
AWARD-1 (dulaglutide vs exenatide ER vs placebo):
- Dulaglutide 1.5 mg: HbA1c reduction 1.64%
- Dulaglutide 0.75 mg: HbA1c reduction 1.31%
- Weight loss: 3.0 kg (1.5 mg) vs 2.2 kg (0.75 mg)
AWARD-3 (dulaglutide vs metformin):
- Dulaglutide 1.5 mg: HbA1c reduction 0.76%
- Superior to metformin monotherapy
AWARD-5 (dulaglutide vs sitagliptin):
- Dulaglutide 1.5 mg: HbA1c reduction 1.57% vs 0.60%
- Superior across all endpoints
AWARD-6 (dulaglutide 1.5 mg vs semaglutide 1.0 mg):
- HbA1c: Dulaglutide −1.42% vs semaglutide −1.64% (semaglutide superior)
- Weight: Dulaglutide −3.6 kg vs semaglutide −5.8 kg (semaglutide superior)
SUSTAIN Program (Semaglutide)
Section titled “SUSTAIN Program (Semaglutide)”SUSTAIN-7 (semaglutide vs dulaglutide — the pivotal head-to-head):
| Endpoint | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|---|
| HbA1c reduction | −1.06% | −1.36% | −0.71% | −1.14% |
| Weight loss | −3.5 kg | −4.3 kg | −2.0 kg | −3.0 kg |
| GI side effects | 17–22% | 17–22% | 10–15% | 10–15% |
SUSTAIN-7 conclusion: Semaglutide 1.0 mg was statistically superior to dulaglutide 1.5 mg for both HbA1c reduction (−1.36% vs −1.14%) and weight loss (−4.3 kg vs −3.0 kg).
Comparative Efficacy Summary
Section titled “Comparative Efficacy Summary”| Parameter | Dulaglutide 1.5 mg | Semaglutide 1.0 mg | Difference |
|---|---|---|---|
| HbA1c reduction | −1.3 to −1.6% | −1.5 to −1.8% | ~0.2% advantage semaglutide |
| Weight loss | −2 to −4 kg | −4 to −6 kg | ~1.5–2 kg advantage semaglutide |
| MACE reduction | 12% (REWIND) | 26% (SUSTAIN-6) | Semaglutide greater |
| CV death | 11% reduction (NS) | 13% reduction (NS) | Similar |
| Postprandial control | Moderate | Moderate-strong | Semaglutide slightly better |
| GI tolerability | Moderate | Moderate | Dulaglutide slightly better |
Cardiovascular Evidence
Section titled “Cardiovascular Evidence”Dulaglutide: REWIND
Section titled “Dulaglutide: REWIND”REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) enrolled 9,901 patients with T2D and mixed CV risk:
- Primary MACE: Dulaglutide reduced MACE by 12% (HR 0.88, p=0.002)
- CV death: Non-significant 11% reduction
- Key distinction: REWIND included 31% of patients without established CV disease — demonstrating primary prevention benefit
Semaglutide: SUSTAIN-6 + SELECT
Section titled “Semaglutide: SUSTAIN-6 + SELECT”- SUSTAIN-6: 26% MACE reduction (HR 0.74, p<0.001) in high CV risk patients
- SELECT: 20% MACE reduction in non-diabetic patients with obesity and CV disease
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Dulaglutide | Semaglutide |
|---|---|---|
| Dose options | 0.75 mg, 1.5 mg | 0.25, 0.5, 1.0, 2.0 mg |
| Titration | 0.75 → 1.5 mg (3 months) | 0.25 → 0.5 → 1.0 mg (4-month increments) |
| Injection device | Trulicity Pen (pre-filled) | Ozempic Pen (dose-selectable) |
| Needle gauge | 29G (hidden) | 32G (hidden) |
| Injection sites | Abdomen, thigh, upper arm | Abdomen, thigh, upper arm |
Dulaglutide’s pre-filled, single-dose pen offers simplicity; semaglutide’s multi-dose pen with dose selection provides more flexible dosing and higher maximum doses.
Safety Comparison
Section titled “Safety Comparison”| Effect | Dulaglutide | Semaglutide |
|---|---|---|
| Nausea | 15–25% | 20–40% |
| Diarrhea | 10–15% | 10–20% |
| Vomiting | 5–10% | 10–20% |
| Constipation | 5–10% | 15–20% |
| Injection site reactions | 2–5% | 1–5% |
| Pancreatitis risk | Rare | Rare |
| Thyroid C-cell tumors | Boxed warning | Boxed warning |
Semaglutide produces more GI side effects, particularly nausea and vomiting, especially during dose titration. Dulaglutide’s slightly better GI tolerability may improve adherence in sensitive patients.
Summary
Section titled “Summary”Semaglutide and dulaglutide are both effective once-weekly GLP-1 RAs, but semaglutide demonstrates superior HbA1c reduction (~0.2%), greater weight loss (~1.5–2 kg), and more robust cardiovascular outcomes (26% vs 12% MACE reduction). Dulaglutide offers better GI tolerability and broader CV prevention evidence (REWIND included non-diabetic patients). The choice depends on clinical priorities: semaglutide for maximum metabolic and cardiovascular benefit, dulaglutide for patients requiring better GI tolerability or those in primary prevention settings.